Andrew Matelis

Artificial Intelligence in Drug Discovery: Translational Bottlenecks, Biomedical Engineering Constraints, and Commercial Realities

The analysis suggests that AI will become an increasingly important component of pharmaceutical workflows; however, long-term impact will depend less on algorithmic advancement alone and more on effective integration with biological validation, experimental rigor, clinical evidence, and scalable translational infrastructure.